28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
17 March 2022 - Due to the FDA action on plinabulin, ICER will not hold a public meeting but has produced ...
3 February 2022 - The prices of drugs used to treat COVID-19 for those at risk of serious illness are ...
25 January 2022 - Registration now open for 1 February “Early Insights” webinar. Public comment period now open until 22 ...
6 January 2022 - Tirzepatide has a novel dual GIP and GLP-1 receptor agonist mechanism of action and is seen as ...
16 November 2021 - Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently ...
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
16 September 2021 - Public comment period now open until 14 October 2021; requests to make oral comment during public ...
10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...
22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting ...
9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns ...
14 May 2021 - Public comment period now open until 11 June 2021; requests to make oral comment during public meeting ...